The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer
about
ErbB receptors: from oncogenes to targeted cancer therapiesMolecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future DirectionsMechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinasesErbB polymorphisms: insights and implications for response to targeted cancer therapeuticsEpidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.HER2 carboxyl-terminal fragments regulate cell migration and cortactin phosphorylationDual HER2 blockade: preclinical and clinical dataChemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of a dual inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 tyrosine kinasesLapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.Lapatinib for the treatment of breast cancer in the People's Republic of China.Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapyThe role of HER2 in cancer therapy and targeted drug deliveryComputational analyses of curcuminoid analogs against kinase domain of HER2Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast CancerLapatinib - Member of a New Generation of ErbB-Targeting Drugs.Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis.Present and future evolution of advanced breast cancer therapy.Testing for HER2 in Breast Cancer: A Continuing Evolution.Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.ERBB3: Multifunctional enabler or primary actor in pancreatic cancer?Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausalLoss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancersEffectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors.Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines.The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer.Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitorsVaccinia virus entry, exit, and interaction with differentiated human airway epithelia.Does lapatinib work against HER2-negative breast cancers?Wnt ligands signal in a cooperative manner to promote foregut organogenesis.pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: a tissue-microarray study with clinic-pathological correlationsLapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.Effective Treatment of Solitary Pituitary Metastasis with Panhypopituitarism in HER2-Positive Breast Cancer by LapatinibActivity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer.Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients.
P2860
Q24683709-535CE093-E568-4C28-A098-D25CA001288FQ26741320-E5B3D33D-AEC1-4EBA-B222-C92752281942Q26752780-1FA119BC-8FA0-4E1F-8013-F0A4768EF3A7Q27649889-1E00163B-E6CF-4C32-860C-9564483BEE94Q28084565-FDDC656B-7AED-4955-97FC-772B4BCEF6D4Q30412086-F165BADF-3EDE-494C-9A71-08714DAFE428Q30474678-99B52DD1-D84B-487A-8E02-7C202BC49BABQ30490783-F8CF5F81-9D0E-4632-B988-B8DA3E8DC72FQ30941327-C7FE78FF-1CA7-4E5C-9AD0-B78A40A4B707Q33302631-BBF01F1A-A896-498C-A505-129A1B9B74CCQ33468432-A4C36983-D924-4788-A920-3DDEAEFF98AFQ33644407-60956A9D-6849-445A-BCEC-03A74C35DF38Q34016491-EA59ACB3-0C28-4B2D-B28D-0786786E7C96Q34023653-88B12B8F-0FB2-4341-B651-8BF6B6061F22Q34054213-78AE134E-D107-42BC-8789-68B078F96F92Q34084939-531DCCC4-320A-43A7-8DD3-8E007E484796Q34095748-BAB50F9D-65DD-4013-97BB-3BDC37B91E05Q34096228-794E5323-AAEB-4A2E-BB25-9CE7D569A13EQ34130669-4860D2FD-52E3-46CA-8F5B-52ED2F3BF7EAQ34274925-4352E064-4093-45A9-86D8-B07879BAE707Q34424285-BC2694DF-665F-4E11-924D-64A0CDA86682Q34551761-530F7B25-BD1E-4046-AEB8-1553E1ABDC4FQ34582111-88AF563F-40D8-476F-A9D4-207E06EA6B95Q34611634-51A63155-9B37-47B3-B4E9-9D3C5526BE0BQ34679149-22F8F2C1-C13A-4A8A-A524-1496C2A31D24Q34928941-56181A57-9279-45DD-9E35-CE7B929592D0Q35002433-50D93A11-100D-45D1-9C6D-9AA0DC80AA6EQ35067562-A6226AFC-2AC7-41A7-BB90-0A0B5AF9272BQ35421284-F3DE53C9-B08E-422E-8E6F-BA8929BD6926Q35879839-F18C0DC4-6DCD-43A8-B4E8-40AEBD0B81E6Q35967385-DC36440C-9912-46D1-A5DA-722CFC1FED12Q36098912-7F9F1E71-42CE-4FE6-877E-3D52A066D403Q36253050-A2DBEF6D-54D8-4811-B366-4F311753B804Q36279862-330DD51B-5C72-4422-BBE2-8F3F97EE1FABQ36289932-303D4956-8EFD-4339-97D0-A72FDD96D369Q36371783-C83A6978-709A-4362-8FB0-814888340CECQ36482601-39D32BCA-7EDE-4674-BE71-240AB38802C1Q36510153-AB4B0E20-B7C6-44BF-9548-E5E4FE8DE95EQ36642955-6B813744-365B-4D1F-9FD5-41AC3761FEBAQ36729467-985ED764-FE1A-47B9-9DEF-C7E3C3872CCC
P2860
The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The characterization of novel, ...... : potential therapy for cancer
@ast
The characterization of novel, ...... : potential therapy for cancer
@en
The characterization of novel, ...... : potential therapy for cancer
@nl
type
label
The characterization of novel, ...... : potential therapy for cancer
@ast
The characterization of novel, ...... : potential therapy for cancer
@en
The characterization of novel, ...... : potential therapy for cancer
@nl
prefLabel
The characterization of novel, ...... : potential therapy for cancer
@ast
The characterization of novel, ...... : potential therapy for cancer
@en
The characterization of novel, ...... : potential therapy for cancer
@nl
P2093
P3181
P1433
P1476
The characterization of novel, ...... : potential therapy for cancer
@en
P2093
C Stubberfield
D M Murray
D W Rusnak
K J Alligood
P304
P3181
P407
P577
2001-10-01T00:00:00Z